

CARPENTIER-EDWARDS
PERIMOUNT THEON
PERICARDIAL AORTIC BIOPROSTHESES

ECLIPSING PERFORMANCE.





PERIMOUNT THEON pericardial aortic bioprostheses are clearly out in front when it comes to sustained performance.^{1,2} By offering surgeons an innovative bioprosthesis incorporating proven long-term durability, hemodynamic stability, ease of implant, and our proprietary Carpentier-Edwards ThermoFix process*, they bring a new dimension of confidence to aortic valve replacement.

Dual-action performance—the ThermoFix process*

Calcification can result when calcium in the circulatory system is attracted to phospholipids and glutaraldehyde residuals in the bioprosthetic tissue.³ Confronting each of these potential calcium binding sites is critical to achieving long-term performance for tissue valves.³ The ThermoFix process is the only dual-action tissue treatment designed to confront calcific structural valve deterioration resulting from residual glutaraldehydes and phospholipids.⁴


- Proven to reduce the risk of calcification uptake by up to 81% over glutaraldehyde-fixed controls.⁴
- Not a reversible or degenerative bonding like other tissue treatments.⁵




Lasting performance

The PERIMOUNT aortic pericardial bioprosthesis platform delivers robust performance with a proven track record of uncompromised durability.


Uncompromised performance has been demonstrated in a multitude of studies



More published data than any other tissue valve




Unmatched 20-year durability



Proven performance

To provide confidence in sustained hemodynamics, PERIMOUNT THEON bioprostheses are based on a tissue valve design with proven long-term hemodynamic stability, and reliable function as late as 17 years after implantation.²



Maximum flow area

A large orifice area helps reduce the risk of patient-prosthesis mismatch

PERIMOUNT THEON RSR valve
(21 mm)




Porcine valve
(21 mm)




The Carpentier-Edwards PERIMOUNT THEON bioprosthesis demonstrates an optimal orifice opening when compared to a competitive porcine valve.

Advanced design results in reduced resistance and minimal turbulence

PERIMOUNT THEON RSR valve
(21 mm)



Porcine valve
(21 mm)




Comparison of turbulent kinetic energy downstream from a 21 mm PERIMOUNT THEON RSR bioprosthesis versus a competitive porcine valve.²³

Streamlined performance

PERIMOUNT THEON bioprostheses optimize annular conformity and suturability. Their low aortic protrusion provides sinotubular junction clearance,^{23,24} while a low cusp height maximizes coronary ostia clearance.

Aortic Protrusion for Aortic Valves—Size 21*



*Drawing not to scale.

*No clinical data are available which evaluate the long-term impact of the Edwards Lifesciences tissue treatment in patients.

References

1. Carpentier-Edwards PERIMOUNT aortic pericardial bioprosthesis 20-year Results. Data on file at Edwards Lifesciences, 2003.
2. Banbury, et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. *Ann Thorac Surg* 2002; 73:1460-5.
3. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: Progress toward understanding and prevention. *Ann Thorac Surg* 2005; 79:1072-80.
4. Data on file. Edwards Lifesciences. RD 795.
5. Chen W, et al. Mechanism of efficacy of 2-amino oleic acid for inhibition of calcification of glutaraldehyde pre-treated porcine bioprosthetic heart valves. *Circulation* 1994;90(1):323-29.
6. Pelletier, et al. Aortic Valve Replacement with the Carpentier-Edwards Pericardial Bioprosthesis: Clinical and Hemodynamic Results. *J Card Surg* 1988; Suppl. V.3.:405-412.
7. Franzen, et al. Aortic Valve Replacement with Pericardial Valves in Patients with Small Aortic Roots. Clinical Results in a Consecutive Series of Patients Receiving 19 and 21mm Prostheses. *Scand Cardiovasc J* 2001; 35;114-118.
8. Aupart M, et al. The influence of age on valve related events with Carpentier-Edwards pericardial valves. *J Cardiovasc Surg* 1995; 36:297-302.
9. Meyns B, et al. Aortic and Mitral Valve Replacement With the Carpentier-Edwards Pericardial Bioprosthesis: Mid-Term Clinical Results. *J Heart Valve Dis* 1993; 2:66-70.
10. Le Tourneau T, et al. Mid-Term Comparative Follow-Up After Aortic Valve Replacement with the Carpentier-Edwards and Pericardial Pericardial Prostheses. *Circulation* 1999; 100[suppl II]:II-11-II-16.
11. Sakamoto Y, et al. Carpentier-Edwards Pericardial Aortic Valve in Middle-aged Patients – Comparison with the St. Jude Medical Valve. *Jpn J Thorac Cardiovasc Surg* 2005; 53:465-469.
12. Perier P, et al. Long-Term Evaluation of the Carpentier-Edwards Pericardial Valve in the Aortic Position. *J Card Surg* 1991; 6;4[suppl]:589-594.
13. Le Tourneau T, et al. Ten-Year Echocardiographic and Clinical Follow-Up of Aortic Carpentier-Edwards Pericardial and Supraannular Prosthesis: A Case-Match Study. *Ann Thorac Surg* 2002; 74:2010-5.
14. Vitale N, et al. Clinical and Hemodynamic Evaluation of Small Perimount Aortic Valves in Patients Aged 75 Years or Older. *Ann Thorac Surg* 2003; 75:35-40.
15. Pellerin P, et al. Carpentier-Edwards Pericardial Bioprosthesis in Aortic Position: Long-Term Follow-up 1980 to 1994. *Ann Thorac Surg* 1995; 60:5292-6.
16. Dellgren G, et al. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. *J Thorac Cardiovasc Surg* 2002; 124:146-54.
17. Frater R, et al. Long-Term Durability and Patient Functional Status of the Carpentier-Edwards® Perimount® Pericardial Bioprosthesis in the Aortic Position. *J Heart Valve Dis* 1998; 7:48-53.
18. Jamieson WR, et al. 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses. *Asian Cardiovasc Thorac Ann* 2006; 14:200-205.
19. Aupart M, et al. Perimount Pericardial Bioprosthesis for Aortic Calcified Stenosis: 18-Year Experience with 1,133 Patients. *J of Heart Valve Dis* 2006; 15:768-776.
20. Results of PubMed search with key words "Carpentier-Edwards", "PERIMOUNT valve", "Hancock valve", "Mosaic valve", and "Biocor valve". PubMed search performed December 2006.
21. Dalmau, et al. The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance. *Interactive Cardiovasc and Thorac Surg* 5 2006; 263-267.
22. Summary of Safety and Effectiveness Data, SJM Biocor Valve and SJM Biocor Supra Valve P040021. Effectiveness outcomes, aortic hemodynamic results from Sahlgrenska University Hospital, Gothenburg, Sweden.
23. Data on File. Edwards Lifesciences. RD 1089.
24. Carpentier-Edwards PERIMOUNT Theon pericardial bioprostheses, models 2700TFX, 2800TFX, and 6900PTFX product inserts—Directions for use—2006. 2007.
25. Data on File. Edwards Lifesciences, 2006.
26. St. Jude Medical SJM Biocor® and SJM Biocor® Supra marketing collateral (ITEM 1860/0705/7.5M/EN/BD).
27. Medtronic Mosaic® and Hancock® II Porcine Bioprostheses Inservice Guide (UC200102908B EN).

Rx only. See instructions for use for full prescribing information.

Edwards, PERIMOUNT THEON and TheraFix are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards and PERIMOUNT are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

Hancock II and Mosaic are trademarks of Medtronic, Inc. SJM Biocor is a trademark of St. Jude Medical.

© 2007 Edwards Lifesciences LLC
All rights reserved. ARO2022



Edwards Lifesciences